← Phreesia overview

Phreesia vs Thomson Reuters Corporation Common Shares: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Phreesia Inc (PHR)

Q3 2026
▼2▲1

Phreesia's Q2 Miss and Client Strain Overshadow Legal Clouds

  • Securities class action and fiduciary duty investigation Multiple law firms filed or reminded investors of a securities class action alleging Phreesia misled investors about slowing demand and weak pharmaceutical marketing commitments. A separate investigation into potential fiduciary duty breaches by directors adds legal uncertainty. These legal risks can pressure the stock by raising concerns about management credibility and future liabilities.

    Legal challenges are a major overhang that can weigh on investor sentiment and the stock price.

  • MediFind launches AI chatbot Chloe Phreesia's MediFind launched an AI chatbot to help patients find and book providers, improving the company's product offering and potentially driving more patient engagement. This innovation could support future revenue growth in the network solutions segment, though its near-term financial impact is uncertain.

    New product launches can signal growth potential and competitive positioning.

  • Q2 revenue and EPS miss estimates Phreesia's second-quarter revenue of $129.46 million slightly missed estimates, and EPS of $0.03 fell well short of the $0.11 consensus. Subscription and payment solutions revenue came in below expectations, though network solutions beat. The miss raises concerns about the company's growth trajectory and profitability.

    Earnings misses directly impact investor confidence and can lead to stock price declines.

  • Q2 results show profitability but client strain Phreesia reported its fifth straight positive net income and strong cash flow, allowing debt paydown and reaffirmed guidance. However, the CFO flagged variability in network solutions revenue, and the CEO noted client strain with revenue per client down 2% sequentially. This mixed picture creates uncertainty about future growth.

    While profitability is positive, the warnings about client strain and revenue variability temper the outlook.

August 2026
▼2▲1

Phreesia's Q2 Miss and Client Strain Overshadow Legal Clouds

  • Securities class action and fiduciary duty investigation Multiple law firms filed or reminded investors of a securities class action alleging Phreesia misled investors about slowing demand and weak pharmaceutical marketing commitments. A separate investigation into potential fiduciary duty breaches by directors adds legal uncertainty. These legal risks can pressure the stock by raising concerns about management credibility and future liabilities.

    Legal challenges are a major overhang that can weigh on investor sentiment and the stock price.

  • MediFind launches AI chatbot Chloe Phreesia's MediFind launched an AI chatbot to help patients find and book providers, improving the company's product offering and potentially driving more patient engagement. This innovation could support future revenue growth in the network solutions segment, though its near-term financial impact is uncertain.

    New product launches can signal growth potential and competitive positioning.

  • Q2 revenue and EPS miss estimates Phreesia's second-quarter revenue of $129.46 million slightly missed estimates, and EPS of $0.03 fell well short of the $0.11 consensus. Subscription and payment solutions revenue came in below expectations, though network solutions beat. The miss raises concerns about the company's growth trajectory and profitability.

    Earnings misses directly impact investor confidence and can lead to stock price declines.

  • Q2 results show profitability but client strain Phreesia reported its fifth straight positive net income and strong cash flow, allowing debt paydown and reaffirmed guidance. However, the CFO flagged variability in network solutions revenue, and the CEO noted client strain with revenue per client down 2% sequentially. This mixed picture creates uncertainty about future growth.

    While profitability is positive, the warnings about client strain and revenue variability temper the outlook.

Latest
▼2▲1

Phreesia's Q2 Miss and Client Strain Overshadow Legal Clouds

  • Securities class action and fiduciary duty investigation Multiple law firms filed or reminded investors of a securities class action alleging Phreesia misled investors about slowing demand and weak pharmaceutical marketing commitments. A separate investigation into potential fiduciary duty breaches by directors adds legal uncertainty. These legal risks can pressure the stock by raising concerns about management credibility and future liabilities.

    Legal challenges are a major overhang that can weigh on investor sentiment and the stock price.

  • MediFind launches AI chatbot Chloe Phreesia's MediFind launched an AI chatbot to help patients find and book providers, improving the company's product offering and potentially driving more patient engagement. This innovation could support future revenue growth in the network solutions segment, though its near-term financial impact is uncertain.

    New product launches can signal growth potential and competitive positioning.

  • Q2 revenue and EPS miss estimates Phreesia's second-quarter revenue of $129.46 million slightly missed estimates, and EPS of $0.03 fell well short of the $0.11 consensus. Subscription and payment solutions revenue came in below expectations, though network solutions beat. The miss raises concerns about the company's growth trajectory and profitability.

    Earnings misses directly impact investor confidence and can lead to stock price declines.

  • Q2 results show profitability but client strain Phreesia reported its fifth straight positive net income and strong cash flow, allowing debt paydown and reaffirmed guidance. However, the CFO flagged variability in network solutions revenue, and the CEO noted client strain with revenue per client down 2% sequentially. This mixed picture creates uncertainty about future growth.

    While profitability is positive, the warnings about client strain and revenue variability temper the outlook.

Q2 2026
▼2

Phreesia Faces Securities Fraud Lawsuits Over Slashed Guidance

  • Securities fraud class action Multiple law firms filed a class action alleging Phreesia misled investors about growth and demand before cutting fiscal 2027 revenue guidance. This legal risk can pressure PHR's stock by raising uncertainty and potential costs.

    The lawsuit is the main new event this period and directly weighs on investor confidence.

  • Lead plaintiff deadline pressure Investors have until July 13, 2026 to seek lead plaintiff status in the class action. The approaching deadline keeps the lawsuit in the news, which can sustain negative sentiment and deter buyers.

    The deadline is a new near-term catalyst that keeps legal overhang visible.

June 2026
▼2

Phreesia Faces Securities Fraud Lawsuits Over Slashed Guidance

  • Securities fraud class action Multiple law firms filed a class action alleging Phreesia misled investors about growth and demand before cutting fiscal 2027 revenue guidance. This legal risk can pressure PHR's stock by raising uncertainty and potential costs.

    The lawsuit is the main new event this period and directly weighs on investor confidence.

  • Lead plaintiff deadline pressure Investors have until July 13, 2026 to seek lead plaintiff status in the class action. The approaching deadline keeps the lawsuit in the news, which can sustain negative sentiment and deter buyers.

    The deadline is a new near-term catalyst that keeps legal overhang visible.

▼2

Phreesia Faces Securities Fraud Lawsuits Over Slashed Guidance

  • Securities fraud class action Multiple law firms filed a class action alleging Phreesia misled investors about growth and demand before cutting fiscal 2027 revenue guidance. This legal risk can pressure PHR's stock by raising uncertainty and potential costs.

    The lawsuit is the main new event this period and directly weighs on investor confidence.

  • Lead plaintiff deadline pressure Investors have until July 13, 2026 to seek lead plaintiff status in the class action. The approaching deadline keeps the lawsuit in the news, which can sustain negative sentiment and deter buyers.

    The deadline is a new near-term catalyst that keeps legal overhang visible.

Thomson Reuters Corporation Common Shares (TRI)

Q3 2026
▲3

AI Restructuring, KKR Deal, and ICE Contract Drive TRI Higher

  • AI-focused restructuring Thomson Reuters cut up to 500 engineering roles and added 250 senior AI positions, aiming to sharpen its AI focus. This restructuring, announced in July, initially lifted the stock as investors saw potential for innovation and efficiency.

    This strategic move was a key positive driver in Q3, signaling a pivot to AI.

  • KKR deal for Global Print stake Thomson Reuters agreed to sell 51% of its Global Print unit to KKR for $500 million. The deal, part of the AI restructuring, was seen as a way to streamline operations and focus on core growth areas.

    This transaction was a significant positive event in Q3, reflecting portfolio optimization.

  • ICE contract for CLEAR Thomson Reuters won a five-year, $125 million contract with ICE for its CLEAR platform. While the deal boosts revenue visibility, it also raises privacy and regulatory concerns that could pose risks.

    This contract was a notable positive development in Q3, though with potential regulatory overhang.

  • Q2 earnings beat and competitive threats Q2 results beat expectations with 8% organic revenue growth and a raised 2026 outlook, boosting confidence. However, Google's Gemini Enterprise for Legal and other rivals threaten pricing power, and a data breach in C-Track exposed records, risking legal costs and reputational damage.

    This captures both the positive earnings surprise and the emerging negative factors that influenced TRI's performance.

August 2026
▲2▼2

Thomson Reuters beats, raises outlook, but faces AI rivals and a data breach

  • Strong Q2 results and raised 2026 outlook Thomson Reuters reported 8% organic revenue growth and raised its full-year outlook, with its key Legal, Corporates and Tax segments growing 10%. Profit and cash flow also rose. This tells investors the core business is accelerating, which supports a higher stock price.

    This is the biggest positive fundamental driver of the period, directly lifting earnings expectations and the stock's value.

  • Earnings beat expected ahead of report Before the results, analysts expected Thomson Reuters to beat estimates, with earnings per share up about 9% and revenue up over 7%. That positive setup likely helped the stock ahead of the actual report, which then confirmed the strength.

    It explains pre-earnings optimism that contributed to the stock's positive momentum into the report.

  • Google and others push into legal AI Google launched Gemini Enterprise for Legal, a competing AI tool for law firms, and other rivals like Anthropic are also expanding. This raises the risk that Thomson Reuters could lose customers or pricing power in its legal AI products, weighing on future growth and the stock.

    It is the main competitive threat this period that could pressure TRI's valuation and market share.

  • Data breach in court records system Unauthorized access to Thomson Reuters' C-Track litigation platform exposed court records in multiple U.S. states and Canada. While operations continue, the incident could lead to legal costs, fines, and reputational damage, making investors cautious and potentially hurting the stock.

    It is a new regulatory and reputational risk that could have financial and trust consequences for TRI.

Latest
▲2▼2

Thomson Reuters beats, raises outlook, but faces AI rivals and a data breach

  • Strong Q2 results and raised 2026 outlook Thomson Reuters reported 8% organic revenue growth and raised its full-year outlook, with its key Legal, Corporates and Tax segments growing 10%. Profit and cash flow also rose. This tells investors the core business is accelerating, which supports a higher stock price.

    This is the biggest positive fundamental driver of the period, directly lifting earnings expectations and the stock's value.

  • Earnings beat expected ahead of report Before the results, analysts expected Thomson Reuters to beat estimates, with earnings per share up about 9% and revenue up over 7%. That positive setup likely helped the stock ahead of the actual report, which then confirmed the strength.

    It explains pre-earnings optimism that contributed to the stock's positive momentum into the report.

  • Google and others push into legal AI Google launched Gemini Enterprise for Legal, a competing AI tool for law firms, and other rivals like Anthropic are also expanding. This raises the risk that Thomson Reuters could lose customers or pricing power in its legal AI products, weighing on future growth and the stock.

    It is the main competitive threat this period that could pressure TRI's valuation and market share.

  • Data breach in court records system Unauthorized access to Thomson Reuters' C-Track litigation platform exposed court records in multiple U.S. states and Canada. While operations continue, the incident could lead to legal costs, fines, and reputational damage, making investors cautious and potentially hurting the stock.

    It is a new regulatory and reputational risk that could have financial and trust consequences for TRI.

July 2026
▲4

TRI Rallies on AI Restructuring, KKR Print Deal, and Government Contract

  • AI-focused restructuring Thomson Reuters announced it will cut up to 500 engineering roles and create over 250 senior AI positions, aiming to accelerate AI-driven growth in legal, tax, and regulatory workflows. Management expects a notable revenue improvement this year, boosting investor confidence.

    This is a major strategic shift that directly impacts future growth and profitability.

  • KKR joint venture for Global Print Thomson Reuters sold a 51% stake in its Global Print business to KKR for about $500 million, retaining 49% and editorial control. The deal brings cash and focuses the company on higher-growth digital and AI areas.

    This capital move strengthens the balance sheet and sharpens strategic focus.

  • Undervaluation after AI pivot An analysis suggests Thomson Reuters stock may be undervalued, trading at 24.4 times earnings versus a fair P/E of 42.0. Despite a 55.9% drop over the past year, the AI restructuring and print deal could support long-term profitability, though execution risk remains.

    This highlights potential upside and addresses the stock's recent weakness.

  • $125M ICE contract for CLEAR Thomson Reuters secured a five-year, $125 million contract with ICE for its CLEAR investigative product, providing access to credit card application data. This adds stable government revenue but raises privacy concerns and potential regulatory scrutiny.

    This new contract demonstrates strong demand for its data services and adds recurring revenue.

▲4

TRI Rallies on AI Restructuring, KKR Print Deal, and Government Contract

  • AI-focused restructuring Thomson Reuters announced it will cut up to 500 engineering roles and create over 250 senior AI positions, aiming to accelerate AI-driven growth in legal, tax, and regulatory workflows. Management expects a notable revenue improvement this year, boosting investor confidence.

    This is a major strategic shift that directly impacts future growth and profitability.

  • KKR joint venture for Global Print Thomson Reuters sold a 51% stake in its Global Print business to KKR for about $500 million, retaining 49% and editorial control. The deal brings cash and focuses the company on higher-growth digital and AI areas.

    This capital move strengthens the balance sheet and sharpens strategic focus.

  • Undervaluation after AI pivot An analysis suggests Thomson Reuters stock may be undervalued, trading at 24.4 times earnings versus a fair P/E of 42.0. Despite a 55.9% drop over the past year, the AI restructuring and print deal could support long-term profitability, though execution risk remains.

    This highlights potential upside and addresses the stock's recent weakness.

  • $125M ICE contract for CLEAR Thomson Reuters secured a five-year, $125 million contract with ICE for its CLEAR investigative product, providing access to credit card application data. This adds stable government revenue but raises privacy concerns and potential regulatory scrutiny.

    This new contract demonstrates strong demand for its data services and adds recurring revenue.